Document is current
Any future updates will be listed below
-
Authors
Mullins-Dansereau, Victor
Myre, Marie-Lou
Bardoul, Angelina
Geoffroy, Karen
Rallo Pita, Marco J
Béland, Delphine
Desaulniers, Kim Leclerc
Roy, Dominic Guy
Bourgeois-Daigneault, Marie-Claude https://orcid.org/0000-0002-9091-2235
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02285816 at ClinicalTrials.govnct02285816 at ClinicalTrials.govDocuments that mention this clinical trial
Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases
https://doi.org/10.1136/bmjonc-2024-000472
Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities
https://doi.org/10.1136/jitc-2024-010570
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
https://doi.org/10.1136/jitc-2020-001387
Documents that mention this clinical trial
Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases
https://doi.org/10.1136/bmjonc-2024-000472
Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities
https://doi.org/10.1136/jitc-2024-010570
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
https://doi.org/10.1136/jitc-2020-001387
-
Funding
Funding for this research was provided by:
Université de Montréal (NA)
Fonds de Recherche du Québec - Santé (NA)
Fondation du cancer du sein du Québec (NA)
Institut Du Cancer de Montréal (NA)
- License Information
